
Releases
Actinium Pharmaceuticals Secures Patent Growth and Listing Extension
Actinium Pharmaceuticals has bolstered its Actimab-A program through a series of new patent acquisitions and expanded manufacturing capabilities. As the company prepares for clinical milestones scheduled through 2027, it also confirmed that the NYSE American has granted a compliance extension, allowing its stock to maintain its current listing.
























